阅读方式:

[Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis]
阿尼芬净治疗食管念珠菌病、念珠菌血症和侵袭性念珠菌病的疗效

出处: Rev Iberoam Micol   2008   Jun   25 (2) :107-18

作者:Montejo Gonzalez JC;Catalan Gonzalez M;Leon Gil C

PMID:18473505

Anidulafungin is a new echinocandin that appears to have several advantages over existing antifungals. It is unique because it slowly degrades in humans, undergoing a process of biotransformation rather than being metabolized. It exhibits high in vitro and in vivo activities against Candida spp. and Aspergillus spp. In several clinical studies investigating Candida esophagitis; candidemia and invasive candidiasis, the clinical efficacy of this echinocandin was similar, or even superior, to that of established antifungals in candidemia. Antifungal activity against strains no longer susceptible to conventional antifungal agents, such as fluconazole and amphotericin B suggests that anidulafungin can be used as salvage therapy in life-threatening fungal infections. The limited toxicity profile, minimal drug-drug interactions and the fact that does not require dosage adjustment in subjects with hepatic or renal impairment, establishes this echinocandin as an attractive new option for the treatment of invasive fungal infections.

阿尼芬净是一种新型棘白菌素类药物,与目前存在的抗真菌药物相比看来有几种优势。该药独特之处在于能在人体内缓慢降解,经历一个生物转化而非被代谢的过程。它在体内外均有较高的抗念珠菌属和曲霉菌属活性。几个调查念珠菌性食管炎、念珠菌血症和侵袭性念珠菌病的临床研究发现,这种棘白菌素类药物的临床疗效类似或优于已被证实治疗念珠菌血症有效的抗真菌药物。抗真菌活性提示,对常规抗真菌药物,例如氟康唑和两性霉素B不再敏感的菌株,阿尼芬净菌能作为威胁生命真菌感染的抢救治疗。有限的毒性、最小的药物相互作用和不需要根据肝肾功能损害调整剂量证实了这种棘白菌素类药物是一种治疗侵袭性真菌感染有吸引力的新选择。